ArticleBiomaterials2013
The use of nanolipoprotein particles to enhance the immunostimulatory properties of innate immune agonists against lethal influenza challenge.
Article in Biomaterials, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 36 citations in OpenAlex.
- Nanolipoprotein particle (NLP) vaccine confers protection againstFrontiers in immunology · 2025Article
- A 30-Year Review on Nanocomposites: Comprehensive Bibliometric Insights into Microstructural, Electrical, and Mechanical Properties Assisted by Artificial Intelligence.Materials (Basel, Switzerland) · 2024Review
- Induction of Protection in Mice against aVaccines · 2021Article
- Nanolipoprotein particles for co-delivery of cystine-knot peptides and Fab-based therapeutics.Nanoscale advances · 2021Article
- A Survey of Preclinical Studies Evaluating Nanoparticle-Based Vaccines Against Non-Viral Sexually Transmitted Infections.Frontiers in pharmacology · 2021Review
- Cationic HDL mimetics enhance in vivo delivery of self-replicating mRNA.Nanomedicine : nanotechnology, biology, and medicine · 2020Article
- Characterization ofFrontiers in immunology · 2020Article
- Article
- Enhancing innate antiviral immune responses in rainbow trout by double stranded RNA delivered with cationic phytoglycogen nanoparticles.Scientific reports · 2019Article
- Nanoparticle Delivery of Immunostimulatory Agents for Cancer Immunotherapy.Theranostics · 2019Review
- Dual TLR agonist nanodiscs as a strong adjuvant system for vaccines and immunotherapy.Journal of controlled release : official journal of the Controlled Release Society · 2018Article
- Lipid composition dictates serum stability of reconstituted high-density lipoproteins: implications for in vivo applications.Nanoscale · 2018Article
- The enhanced antitumor-specific immune response with mannose- and CpG-ODN-coated liposomes delivering TRP2 peptide.Theranostics · 2018Article
- Effects of engineered nanoparticles on the innate immune system.Seminars in immunology · 2017Review
- Cell-free production of a functional oligomeric form of aThe Journal of biological chemistry · 2017Article
- Characterization of Innate Responses Induced by PLGA Encapsulated- and Soluble TLR Ligands In Vitro and In Vivo in Chickens.PloS one · 2017Article
- Review
- Immunomodulation of nanoparticles in nanomedicine applications.BioMed research international · 2014Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 3 institutions in 1 country.
Funding
Abstract
Recent studies have demonstrated that therapies targeting the innate immune system have the potential to provide transient, non-specific protection from a variety of infectious organisms; however, the potential of enhancing the efficacy of such treatments using nano-scale delivery platforms requires more in depth evaluation. As such, we employed a nanolipoprotein (NLP) platform to enhance the efficacy of innate immune agonists. Here, we demonstrate that the synthetic Toll-like receptor (TLR) agonists monophosphoryl lipid A (MPLA) and CpG oligodeoxynucleotides (CpG) can be readily incorporated into NLPs. Conjugation of MPLA and CpG to NLPs (MPLA:NLP and CpG:NLP, respectively) significantly enhanced their immunostimulatory profiles both in vitro and in vivo compared to administration of agonists alone, as evidenced by significant increases in cytokine production, cell surface expression of activation markers, and upregulation of immunoregulatory genes. Importantly, enhancement of cytokine production by agonist conjugation to NLPs was also observed in primary human dendritic cells. Furthermore, BALB/c mice pretreated with CpG:NLP constructs survived a lethal influenza challenge whereas pretreatment with CpG alone had no effect on survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.